Printer Friendly

Orexigen Therapeutics announces in-licensing of key patents to further strengthen its intellectual property estate for contrave.

Orexigen Therapeutics, Inc. (San Diego, CA), a biopharmaceutical company focused on the treatment of obesity, announced the licensing of certain intellectual property (IP) from GlaxoSmithKline (GSK) that expands the company's IP position underlying Contrave, its lead product candidate for the treatment of obesity.

"This license agreement with GSK complements the IP foundation of Contrave, providing us with additional product formulation options as we pursue regulatory approval and potential commercialization of Contrave," said Michael Narachi, President and Chief Executive Officer, Orexigen Therapeutics.

In exchange for undisclosed upfront and future milestone payments, Orexigen secured non-exclusive rights to certain formulation patents related to bupropion, one of the constituents of Contrave. The transaction is not expected to materially impact the company's financial position. Top line results of the first of four Phase 3 clinical trials for Contrave, NB-302, were announced January 2009. Results from the three other Phase 3 clinical trials (NB-301, NB-303, NB-304) are expected to be announced in the third quarter of 2009. Pending positive results, the company is on track to submit a New Drug Application (NDA) with the FDA in the first half of 2010.

Orexigen Therapeutics is a biopharmaceutical company focused on the treatment of obesity. The company's lead combination product candidates targeted for obesity are Contrave, which is in Phase 3 clinical trials, and Empatic, which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss.

Orexigen Therapeutics, Inc.

+1-858-875-8600

www.orexigen.com
COPYRIGHT 2009 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Comment:Orexigen Therapeutics announces in-licensing of key patents to further strengthen its intellectual property estate for contrave.
Publication:BIOTECH Patent News
Geographic Code:1CANA
Date:May 1, 2009
Words:264
Previous Article:Neuromed announces that Merck & Co., Inc. terminates research collaboration and license agreement for compounds targeting N-type calcium channels.
Next Article:RainEarth applies for patent for second generation blood dialysis equipment.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters